Download these slides for expert insights on key trials presented at ECCO 2022 and the impact the data will have in the management of patients with Crohn disease and ulcerative colitis.
Recent acceleration in the development of biologics and small-molecule inhibitors for patients with inflammatory bowel disease has led to an expanded and increasingly complex treatment landscape. Here’s my take.
In this webcast, expert faculty translate and discuss the most clinically significant data from ECCO 2022 into evidence-based management strategies for patients with Crohn disease and ulcerative colitis.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.